Vaxxinity (NASDAQ:VAXX) Trading 2.1% Higher

Shares of Vaxxinity, Inc. (NASDAQ:VAXX) traded up 2.1% during mid-day trading on Tuesday . The company traded as high as $0.67 and last traded at $0.65. 149,374 shares were traded during trading, a decline of 61% from the average session volume of 386,936 shares. The stock had previously closed at $0.63.

Vaxxinity Price Performance

The firm has a 50 day moving average price of $0.71 and a 200 day moving average price of $0.86. The stock has a market capitalization of $82.08 million, a PE ratio of -1.44 and a beta of 2.39. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 0.99.

Institutional Trading of Vaxxinity

A number of hedge funds and other institutional investors have recently bought and sold shares of VAXX. ExodusPoint Capital Management LP bought a new position in shares of Vaxxinity during the 1st quarter valued at approximately $27,000. Citigroup Inc. bought a new stake in shares of Vaxxinity during the 2nd quarter valued at $32,000. California State Teachers Retirement System purchased a new position in shares of Vaxxinity during the 2nd quarter valued at $36,000. Tower Research Capital LLC TRC boosted its holdings in Vaxxinity by 3,640.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 14,962 shares of the company’s stock worth $34,000 after buying an additional 14,562 shares during the period. Finally, Bank of America Corp DE increased its stake in Vaxxinity by 7,829.0% in the 1st quarter. Bank of America Corp DE now owns 15,858 shares of the company’s stock worth $68,000 after buying an additional 15,658 shares in the last quarter. Hedge funds and other institutional investors own 82.95% of the company’s stock.

About Vaxxinity

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD.